Loading patent…
AssigneesTiffani C. Chance, Capricor, Inc., The Government of the United States, as represented by the Secretary of the Army
InventorsTiffani C. Chance, James A. Bynum, Linda S. Marban
Estimating the term…
The present invention generally relates to the use of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) as an anti-shock therapeutic. For instance, the present invention relates to a method of using CDC-EVs to treat polytrauma associated with coagulopathy and hemorrhagic shock in a subject in need thereof, wherein the lactate, glucose and/or creatinine levels in the subject are decreased upon being treated with a therapeutically effective amount of CDC-EVs. The results presented herein are of great relevance to the development of EV products for use in combat casualty care, as the studies presented herein show that CDC-EVs have the potential to be an anti-shock therapeutic if administered immediately after injury involving trauma associated with hemorrhagic shock and/or coagulopathy.
A method of treating polytrauma in a mammalian subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) immediately or within a short time period after polytrauma, wherein said polytrauma is associated with coagulopathy and hemorrhagic shock.
A method of decreasing the risks associated with polytrauma in a mammalian subject suffering from polytrauma comprising the step of:
A method of treating trauma in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs).
The method according to claim 5, wherein said trauma is associated with, or is coupled with, or is induced by, coagulopathy and/or hemorrhagic shock.
A method of treating coagulopathy in a subject in need thereof, the method comprising the step of administering to the subject a therapeutically effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs).
A method of decreasing lactate, glucose and/or creatinine levels in a subject suffering from trauma, the method comprising administering to the subject a therapeutically effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs).
A method of decreasing lactate, glucose and/or creatinine levels in a subject suffering from coagulopathy, the method comprising administering to the subject a therapeutically effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs).
A method of decreasing the risk of shock in a subject suffering from trauma, the method comprising administering to the subject a therapeutically effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs).
A method of decreasing the risk of shock in a subject suffering from coagulopathy, the method comprising administering to the subject a therapeutically effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs).
A method of treating trauma to an organ in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs).
A formulation comprising extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) and at least one pharmaceutically acceptable carrier for use in treating polytrauma in a subject in need thereof, wherein said polytrauma is associated with coagulopathy and hemorrhagic shock.
A formulation comprising extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) for use in treating trauma in a subject in need thereof.
A formulation comprising extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) for use in treating coagulopathy in a subject in need thereof.
A formulation comprising extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) for use in a method of decreasing the lactate, glucose and/or creatinine levels in a subject suffering from trauma, the method comprising administering to the subject a therapeutically effective amount of CDC-EVs.
A formulation comprising extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) for use in a method of in decreasing the lactate, glucose and/or creatinine levels in a subject suffering from coagulopathy, the method comprising administering to the subject a therapeutically effective amount of CDC-EVs.
A formulation comprising extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) for use in a method of in decreasing the risk of shock in a subject suffering from trauma, the method comprising administering to the subject a therapeutically effective amount of CDC-EVs.
A formulation comprising extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) for use in a method of decreasing the risk of shock in a subject suffering from coagulopathy, the method comprising administering to the subject a therapeutically effective amount of CDC-EVs.
A formulation comprising extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) for use in a method of treating trauma to an organ in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of CDC-EVs.
A method of treating shock subsequent to trauma and hemorrhage in a mammalian subject, comprising administering to the subject a therapeutically effective amount of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs).
Dependencies are inferred from the claim text.